3.2 Baseline Characteristics of the Two Groups

From Research on Pei Zhengxue's Formulation Series · Read time 1 min · Updated March 22, 2026

Keywords：方药研究, 实验研究, 配方资产, 转化沟通, 2.4 测定抑瘤率和脾脏胸腺指数

Section Index

Quality of life was assessed using the Karnofsky score. The pre-treatment quality of life of the two groups is shown in Table 3.

Table 3 Pre-treatment Quality of Life of the Two Groups (X̄±S)

Group	Number of Cases	Karnofsky (X̄±S)	P
Treatment Group	35	64.53±8.440
Control Group	35	67.41±7.762	0.634

Note: The pre-treatment quality of life of the two groups was not statistically significant by t-test, P>0.05, indicating comparability.

The AFP levels of the two groups are shown in Table 4.

Table 4 Pre-treatment AFP Levels of the Two Groups (Unit: ng/ml)

Group	Number of Cases	<30	30~400	>1000
Treatment Group	35	12	15	8
Control Group	35	8	18	9

Note: The pre-treatment AFP levels of the two groups were not statistically significant by rank-sum test, P>0.05, indicating comparability.

The liver function of the two groups was measured using ALT, AST, and γ-GT as indicators. Their pre-treatment values are shown in Table 5.

Table 5 Pre-treatment ALT Values of the Two Groups (X̄±S) (Unit: U/L)

Group	Number of Cases	ALT	AST	γ-GT
Treatment Group	35	85.36±23.437	77.09±18.286	92.97±19.855
Control Group	35	91.15±18.768	76.03±17.011	83.68±20.418

Note: The pre-treatment ALT, AST, and γ-GT values of the two groups were not statistically significant by t-test, P>0.05.

The kidney function of the two groups was measured using BUN and Cr as indicators. Their pre-treatment values are shown in Table 6.

Table 6 Pre-treatment BUN and Cr Values of the Two Groups (X̄±S) (Units: mmol/L and μmol/L, respectively)

Group	Number of Cases	BUN	Cr
Treatment Group	35	5.494±0.901	79.24±20.006
Control Group	35	4.803±0.920	81.94±19.486

Note: The pre-treatment BUN and Cr values of the two groups were not statistically significant by t-test, P>0.05.

The complete blood count of the two groups was measured using WBC, RBC, and HGB as indicators. Their pre-treatment values are shown in Table 7.

Table 7 Pre-treatment WBC, RBC, and HGB Values of the Two Groups (X̄±S) (Units: ×10⁹/L, ×10¹²/L, g/L, respectively)

Group	Number of Cases	WBC	RBC	HGB
Treatment Group	35	7.635±1.992	4.338±0.429	111.32±15.505
Control Group	35	8.132±2.227	3.962±0.773	109.15±17.308

Note: The pre-treatment WBC, RBC, and HGB values of the two groups were not statistically significant by t-test, P>0.05.

This chapter is prepared for online research and reading; for external materials, please align with original publications and the review process.